{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:42Z","timestamp":1791357342087,"version":"4.3.1"},"reference-count":67,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamapsychiatry.2020.2453","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T15:44:05Z","timestamp":1596642245000},"page":"1246","source":"Crossref","is-referenced-by-count":121,"title":["Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects"],"prefix":"10.1001","volume":"77","author":[{"given":"Kayla N.","family":"Anderson","sequence":"first","affiliation":[{"name":"Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Lind","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"},{"name":"United States Public Health Service, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Simeone","sequence":"additional","affiliation":[{"name":"Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Bobo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen A.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Slone Epidemiology Center at Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Riehle-Colarusso","sequence":"additional","affiliation":[{"name":"Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara N.","family":"Polen","sequence":"additional","affiliation":[{"name":"Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennita","family":"Reefhuis","sequence":"additional","affiliation":[{"name":"Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"yoi200049r6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15585\/mmwr.mm6503a1","article-title":"Antidepressant prescription claims among reproductive-aged women with private employer-sponsored insurance\u2014United States 2008\u20132013.","volume":"65","author":"Dawson","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"283","key":"yoi200049r7","first-page":"1","article-title":"Antidepressant use among persons aged 12 and over: United States, 2011\u20132014.","author":"Pratt","year":"2017","journal-title":"NCHS Data Brief"},{"issue":"8","key":"yoi200049r8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1089\/jwh.2011.3466","article-title":"Depression and treatment among U.S. pregnant and nonpregnant women of reproductive age, 2005-2009.","volume":"21","author":"Ko","year":"2012","journal-title":"J Womens Health (Larchmt)"},{"issue":"11","key":"yoi200049r9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/bdra.v106.11","article-title":"Using insurance claims data to identify and estimate critical periods in pregnancy: an application to antidepressants.","volume":"106","author":"Ailes","year":"2016","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"2","key":"yoi200049r10","doi-asserted-by":"publisher","first-page":"194.e1","DOI":"10.1016\/j.ajog.2007.07.036","article-title":"Use of antidepressant medications during pregnancy: a multisite study.","volume":"198","author":"Andrade","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"yoi200049r11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/1471-2393-14-242","article-title":"Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance.","volume":"14","author":"Hanley","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"issue":"3","key":"yoi200049r12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.genhosppsych.2012.12.010","article-title":"National trends in antidepressant medication treatment among publicly insured pregnant women.","volume":"35","author":"Huybrechts","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"yoi200049r14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bpobgyn.2015.04.004","article-title":"Depression during pregnancy.","volume":"29","author":"Pearlstein","year":"2015","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"7","key":"yoi200049r15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.euroneuro.2019.06.007","article-title":"Impact of antidepressant use, discontinuation, and dosage modification on maternal depression during pregnancy.","volume":"29","author":"B\u00e9rard","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"yoi200049r16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/(ISSN)1098-240X","article-title":"Relationships among maternal-fetal attachment, prenatal depression, and health practices in pregnancy.","volume":"24","author":"Lindgren","year":"2001","journal-title":"Res Nurs Health"},{"key":"yoi200049r17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/icd.679","article-title":"Maternal depression and dyadic interaction: the role of maternal attachment style.","volume":"19","author":"Flykt","year":"2010","journal-title":"Inf Child Dev."},{"issue":"12","key":"yoi200049r18","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/1471-0528.14144","article-title":"Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.","volume":"123","author":"Eke","year":"2016","journal-title":"BJOG"},{"issue":"1","key":"yoi200049r19","doi-asserted-by":"publisher","first-page":"57.e1","DOI":"10.1016\/j.ajog.2018.08.030","article-title":"Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis.","volume":"220","author":"Masarwa","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"yoi200049r20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40263-016-0338-3","article-title":"Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence.","volume":"30","author":"Alwan","year":"2016","journal-title":"CNS Drugs"},{"issue":"10","key":"yoi200049r21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/pds.3661","article-title":"First-trimester exposure to bupropion and risk of cardiac malformations.","volume":"23","author":"Louik","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"yoi200049r22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/bcpt.12497","article-title":"First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review.","volume":"118","author":"Lassen","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"yoi200049r23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00228-017-2269-4","article-title":"The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies.","volume":"73","author":"Tak","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"yoi200049r24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/bcp.v81.4","article-title":"The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.","volume":"81","author":"B\u00e9rard","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"yoi200049r25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12916-018-1193-5","article-title":"Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births.","volume":"16","author":"Gao","year":"2018","journal-title":"BMC Med"},{"issue":"4","key":"yoi200049r26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1701-2163(15)30965-8","article-title":"The fetal safety of fluoxetine: a systematic review and meta-analysis.","volume":"35","author":"Riggin","year":"2013","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"yoi200049r27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/bcp.v83.4","article-title":"Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.","volume":"83","author":"Shen","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"yoi200049r28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/(ISSN)1096-9926","article-title":"The interaction between dysmorphology and epidemiology: methodologic issues of lumping and splitting.","volume":"45","author":"Khoury","year":"1992","journal-title":"Teratology"},{"issue":"2","key":"yoi200049r30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdra.20641","article-title":"First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.","volume":"88","author":"Bakker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"1","key":"yoi200049r31","doi-asserted-by":"publisher","first-page":"e013372","DOI":"10.1136\/bmjopen-2016-013372","article-title":"Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort.","volume":"7","author":"B\u00e9rard","year":"2017","journal-title":"BMJ Open"},{"key":"yoi200049r32","doi-asserted-by":"publisher","first-page":"h1798","DOI":"10.1136\/bmj.h1798","article-title":"Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.","volume":"350","author":"Furu","year":"2015","journal-title":"BMJ"},{"issue":"26","key":"yoi200049r33","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1056\/NEJMoa067407","article-title":"First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.","volume":"356","author":"Louik","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"yoi200049r34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/AOG.0b013e318220edcc","article-title":"Selective serotonin reuptake inhibitors and risk for major congenital anomalies.","volume":"118","author":"Malm","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"6","key":"yoi200049r35","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/EDE.0000000000000157","article-title":"Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot.","volume":"25","author":"Yazdy","year":"2014","journal-title":"Epidemiology"},{"issue":"11","key":"yoi200049r36","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s10654-015-0065-y","article-title":"Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.","volume":"30","author":"Wemakor","year":"2015","journal-title":"Eur J Epidemiol"},{"issue":"25","key":"yoi200049r37","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa1312828","article-title":"Antidepressant use in pregnancy and the risk of cardiac defects.","volume":"370","author":"Huybrechts","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"yoi200049r38","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1056\/NEJMoa066584","article-title":"Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.","volume":"356","author":"Alwan","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"yoi200049r39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/0091270010373928","article-title":"Patterns of antidepressant medication use among pregnant women in a United States population.","volume":"51","author":"Alwan","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"yoi200049r40","doi-asserted-by":"publisher","first-page":"52.e1","DOI":"10.1016\/j.ajog.2010.02.015","article-title":"Maternal use of bupropion and risk for congenital heart defects.","volume":"203","author":"Alwan","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"yoi200049r41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/bdra.v97.1","article-title":"Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007.","volume":"97","author":"Polen","year":"2013","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"yoi200049r42","doi-asserted-by":"publisher","first-page":"h3190","DOI":"10.1136\/bmj.h3190","article-title":"Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports.","volume":"351","author":"Reefhuis","year":"2015","journal-title":"BMJ"},{"issue":"8","key":"yoi200049r43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/bdra.23384","article-title":"The national birth defects prevention study: a review of the methods.","volume":"103","author":"Reefhuis","year":"2015","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"10","key":"yoi200049r44","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/(ISSN)1542-0760","article-title":"Seeking causes: classifying and evaluating congenital heart defects in etiologic studies.","volume":"79","author":"Botto","year":"2007","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"3","key":"yoi200049r45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/(ISSN)1542-0760","article-title":"Guidelines for case classification for the national birth defects prevention study.","volume":"67","author":"Rasmussen","year":"2003","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"3","key":"yoi200049r46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection.","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"yoi200049r47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/aje\/kwm355","article-title":"Invited commentary: variable selection versus shrinkage in the control of multiple confounders.","volume":"167","author":"Greenland","year":"2008","journal-title":"Am J Epidemiol"},{"key":"yoi200049r49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","article-title":"Moving to a world beyond \u2018p <0.05\u2019.","volume":"73","author":"Wasserstein","year":"2019","journal-title":"Am Stat"},{"issue":"1","key":"yoi200049r50","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.4088\/JCP.14m09241","article-title":"Selective serotonin reuptake inhibitors and congenital heart anomalies: comparative cohort studies of women treated before and during pregnancy and their children.","volume":"77","author":"Petersen","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"yoi200049r51","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001148","article-title":"Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study.","volume":"2","author":"Jimenez-Solem","year":"2012","journal-title":"BMJ Open"},{"issue":"12","key":"yoi200049r52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165122","article-title":"Selective serotonin reuptake inhibitor (SSRI) antidepressants in pregnancy and congenital anomalies: analysis of linked databases in Wales, Norway, and Funen, Denmark.","volume":"11","author":"Jordan","year":"2016","journal-title":"PLoS One"},{"key":"yoi200049r53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.reprotox.2019.01.003","article-title":"Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study.","volume":"84","author":"Richardson","year":"2019","journal-title":"Reprod Toxicol"},{"issue":"10","key":"yoi200049r54","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1176\/appi.ajp.158.10.1728","article-title":"Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study.","volume":"158","author":"Einarson","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi200049r55","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/(ISSN)1542-9741","article-title":"Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.","volume":"83","author":"Oberlander","year":"2008","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"6","key":"yoi200049r56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/jcp.0b013e31815ac4d2","article-title":"Delivery outcome in relation to maternal use of some recently introduced antidepressants.","volume":"27","author":"Lennest\u00e5l","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"yoi200049r57","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ajog.2004.09.027","article-title":"Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study.","volume":"192","author":"Chun-Fai-Chan","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"yoi200049r58","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/(ISSN)1099-1557","article-title":"Bupropion in pregnancy and the prevalence of congenital malformations.","volume":"16","author":"Cole","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"yoi200049r59","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/pds.v21.11","article-title":"Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants.","volume":"21","author":"Thyagarajan","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"yoi200049r60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00228-011-1154-9","article-title":"Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.","volume":"68","author":"Grzeskowiak","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"yoi200049r61","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/(ISSN)1099-1557","article-title":"Positive predictive value of computerized records for major congenital malformations.","volume":"17","author":"Cooper","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"yoi200049r62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/bfm.2010.0019","article-title":"Antidepressant drugs and breastfeeding: a review of the literature.","volume":"6","author":"Davanzo","year":"2011","journal-title":"Breastfeed Med"},{"issue":"4","key":"yoi200049r63","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.4088\/JCP.12r07968","article-title":"The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis.","volume":"74","author":"Grigoriadis","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi200049r64","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1176\/appi.ajp.2008.08081170","article-title":"Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.","volume":"166","author":"Wisner","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"4","key":"yoi200049r65","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.4088\/JCP.12r07966","article-title":"Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence.","volume":"74","author":"Grigoriadis","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"9665","key":"yoi200049r66","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"yoi200049r67","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/acps.2012.127.issue-2","article-title":"Antidepressant use in pregnancy: a critical review focused on risks and controversies.","volume":"127","author":"Byatt","year":"2013","journal-title":"Acta Psychiatr Scand"},{"key":"yoi200049r29","first-page":"595","volume-title":"Pharmacoepidemiology","author":"Mitchell","year":"1994","edition":"2nd Edition"},{"key":"yoi200049r48","volume-title":"Case-control Studies: Design, Conduct, and Analysis.","author":"Schlessman","year":"1982"},{"key":"yoi200049r1","unstructured":"National Institute of Mental Health. Statistics. Accessed August 20, 2019. https:\/\/www.nimh.nih.gov\/health\/statistics\/index.shtml"},{"key":"yoi200049r2","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd edition. Accessed August 20, 2019. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"key":"yoi200049r3","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Accessed August 20, 2019. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/ocd.pdf"},{"key":"yoi200049r4","unstructured":"National Institute for Health and Care Excellence. Clinical guideline [CG113]: generalized anxiety disorder and panic disorder in adults: management. Accessed August 20, 2019. https:\/\/www.nice.org.uk\/guidance\/cg113\/chapter\/1-guidance"},{"key":"yoi200049r5","unstructured":"National Institute for Health and Care Excellence. Clinical guideline [CG159]: social anxiety disorder: recognition, assessment, and treatment. Accessed August 20, 2019. https:\/\/www.nice.org.uk\/guidance\/CG159"},{"key":"yoi200049r13","unstructured":"American College of Obstetrics and Gynecology. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists, number 92, use of psychiatric medications during pregnancy and lactation. Accessed August 20, 2019. https:\/\/www.acog.org\/Clinical-Guidance-and-Publications\/Practice-Bulletins-List"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2769190\/jamapsychiatry_anderson_2020_oi_200049_1606923685.3513.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T10:27:23Z","timestamp":1723372043000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2769190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.2453","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}